Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone loss could be involved in colon cancer

10.10.2014

Like diabetes, colon cancer may be caused in part by the loss of 1 hormone, suggesting hormone replacement therapy could stall cancer formation

Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.

The researchers at Thomas Jefferson University examined colon cancer samples from 281 patients and compared those tissues to nearby colon tissue that wasn't cancerous. They found that guanylin production – measured by number of messenger RNAs for guanylin contained in each cell – decreased 100 to 1,000 times in more than 85 percent of colon cancers tested. They verified their results by also staining for the guanylin hormone production in slices of the tissue samples. They could detect no guanylin hormone in the cancer samples.

In addition, the researchers found that people over 50 years old produced much less of the hormone in their normal colon cells, which could help explain the increase in colon cancer risk in older individuals. The research publishing online October 10th in Cancer, Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR).

"The fact that the vast majority of cancers stop producing this hormone leads us to believe that guanylin may be driving the growth of the tumors," says senior author Scott Waldman, M.D., Ph.D., Chair of the Department of Pharmacology & Experimental Therapeutics and the Samuel MV Hamilton Professor at Thomas Jefferson University If confirmed, "We could prevent colon cancer by giving patients hormone replacement therapy with guanylin." Colon cancer is the second leading cause of death from cancer for men and women and expected to cause 50,000 deaths in 2014, according to the American Cancer Society.

Earlier work has shown that guanylin is a locally-acting hormone, produced by the very cells it acts on. Guanylin activates a receptor called GUCY2C (pronounced "goosy toosy" by researchers). GUC2YC signaling is critical to helping replenish the skin cells lining the gut, and maintaining their overall function. Since the skin of the gut turns over about once every 3 days day, the proper control and maintenance of the signals that replenish the skin is essential. Without signals that maintain cell division, aberrant cell division is more likely to occur, which can lead to cancer.

When guanylin is diminished, the cells of the colon produce more GUCY2C receptors in order to try to catch any possible signal from the outside of the cell. As a result, many colon cancers exhibit high numbers of GUCY2C receptors, despite the fact that the receptor no longer receive the hormone signal that help them activate programming that maintains the health and normal function of the cell.

The next steps, says Waldman, are to test whether hormone replacement can prevent colon cancer development and/or growth in mice, which could then be followed by tests in humans. In addition the team is working on understanding how exactly guanylin functions to maintain the normal health of colon cells.

###

These studies were supported by grants from the National Institutes of Health (R01 CA75123, R01 CA95026, RC1 CA146033, P30 CA56036, R01 CA170533), the Pennsylvania Department of Health (SAP #4100059197, SAP #4100051723), and Targeted Diagnostic and Therapeutics Inc. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations or conclusions. The authors report no conflicts of interest.

For more information, contact Edyta Zielinska, 215-955-5291, edyta.zielinska@jefferson.edu.

About Jefferson

Thomas Jefferson University (TJU), the largest freestanding academic medical center in Philadelphia, is nationally renowned for medical and health sciences education and innovative research. Thomas Jefferson University includes the Sidney Kimmel Medical College (SKMC), one of the largest private medical schools in the country and ranked among the nation's best medical schools by U.S. News & World Report, the Graduate School of Biomedical Sciences and the Jefferson Schools of Nursing, Pharmacy, Health Professions, and Population Health. Jefferson University Physicians is TJU's multi-specialty physician practice consisting of the full-time faculty of SKMC. Thomas Jefferson University partners with its clinical affiliate, Thomas Jefferson University Hospitals.

Article Reference: C. Wilson, et al., "The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer," Cancer Epidemiol Biomarkers, doi: 10.1158/1055-9965.EPI-14-0440, 2014.

Edyta Zielinska | Eurek Alert!

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>